USPTO Patent Grants - Peptides (C07K)

Fusion Protein Enzyme for Biocatalytic Reduction of Cystine to Cysteine

USPTO granted patent US12600995B2 to Wacker Chemie AG for a fusion protein enzyme combining thioredoxin and thioredoxin reductase activities from E. coli to catalyze the reduction of cystine to cysteine. The patent contains 7 claims and was assigned CPC classifications related to biochemistry and peptide chemistry.

Multiplex Genome Editing of Immune Cells for Enhanced Functionality and Resistance to Suppressive Environment

The USPTO granted patent US12600944B2 to the Board of Regents, The University of Texas System covering methods for multiplex genome editing of immune cells, including disruption of multiple genes and insertion of chimeric antigen receptors at specific gene loci. The patent names Rafet Basar, Elizabeth Shpall, and Katy Rezvani as inventors and contains 14 claims. The filing date was November 27, 2019.

Method for Preparing Hemogenic Endothelium Cell and Hematopoietic Stem Cell

USPTO granted Patent US12600954B2 to Allife Medicine (Beijing) Limited on April 14, 2026, covering methods for preparing hematopoietic endothelial cells and hematopoietic stem cells or hematopoietic stem and progenitor cells. The methods use transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG during induced pluripotent stem cell differentiation. The patent application was filed March 19, 2025, and contains 11 claims.

US12600990B2 - mRNA Induced Expression of BMP and Receptor and Methods Related Thereto

USPTO granted patent US12600990B2 to inventors Alexander Day and Bradford Mullin covering methods of preparing synthetic mRNA encoding bone morphogenic protein (BMP) and/or BMP receptor in lipid-solubilized carriers for intraoperative delivery to bone fusion beds. The patent includes 20 claims and covers CPC classifications including C12N 15/88, A61K 47/543, A61K 48/0041, and C07K 14/51.

Method of Determining or Influencing Chondrogenic Potential of Mesenchymal Stromal Cells

USPTO granted Patent US12600952B2 to AO TECHNOLOGY AG on April 14, 2026. The patent covers methods of increasing chondrogenic potential of mesenchymal stromal cells (MSCs) by manipulating TGFβR1, TGFβR2, and ACVRL1 expression levels. The patent contains 23 claims and has 5 CPC classifications spanning cell therapy and peptide technologies.

AB Enzymes Xylanase Variants - Patent US12600960B2

The USPTO granted Patent US12600960B2 to AB Enzymes Finland Oy for xylanase variant polypeptides comprising amino acid sequences with at least 79% but less than 100% identity to SEQ ID NO: 1, featuring at least one disulfide bridge and amino acid substitutions at positions 23 and/or 28. The patent covers the variant polypeptide, fusion proteins, enzyme compositions, recombinant host cells for production, and methods of use.

Carbohydrate Binding Module Variants and Hybrid Polypeptides Comprising Same

USPTO granted Patent US12600996B2 to Novozymes A/S on April 14, 2026, covering cellobiohydrolase variants and carbohydrate binding module variants. The patent also protects polynucleotides encoding the variants, nucleic acid constructs, vectors, host cells, and associated production methods. The patent contains 33 claims and was filed under application number 17812259.

Beta Ketoacyl Synthase IV Variants by CORBION BIOTECH

USPTO granted Patent US12600994B2 to CORBION BIOTECH, INC. covering non-natural variant β-ketoacyl-ACP synthase (KAS) IVa enzymes, polynucleotides encoding such variants, host cells expressing such variants, and oils and oil products produced by such cells. The patent names Joshua Ferreira, Janice Lau Wee, and Nien-Hsi Ko as inventors. Filing date was January 15, 2021, with 21 claims granted.

ELTA Patent - Enzymatic ADP-ribose Labeling Methods

USPTO granted patent US12601734B2 to Johns Hopkins University covering ELTA (Enzymatic Labeling of Terminal ADP-ribose) technology for labeling free, protein-conjugated, or nucleic acid-conjugated ADP-ribose molecules at their 2'-OH termini. The patent contains 28 claims and covers applications including fluorescence-based biophysical measurement of PAR-protein interaction, detection of PAR length from cells, and enrichment of ADP-ribosylated peptides for mass spectrometry identification.

Antibody for Binding to Interleukin 4 Receptor

USPTO granted Patent US12600771B2 to Connect Biopharma Hong Kong Limited for an antibody capable of binding to the interleukin 4 (IL-4) receptor. The patent covers the antibody itself, encoding nucleic acids, vectors, host cells, production methods, medical uses, and kits. The patent contains 30 claims and was filed on November 15, 2023.

CAR T Cell Therapy Patent - US12600775B2

USPTO granted Patent US12600775B2 to Kite Pharma, Inc. for methods of preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy and their use in cell therapy. The patent covers CAR T cell therapy methods with applications in cancer treatment.

Chimeric Antigen Receptors Targeting CD79B and CD19 for Cancer Treatment

USPTO granted Patent US12600760B2 to The General Hospital Corporation on April 14, 2026, covering chimeric antigen receptors (CARs) targeting CD79B and CD19 for cancer treatment. The patent includes methods for producing T cells with CARs having extracellular domains that bind both CD79b and CD19. Invented by Marcela V. Maus, the patent covers upfront treatment methods where the patient has not been previously treated for the cancer.

Peptide Amide Composition for Kappa Opioid Receptor Treatment

USPTO granted Patent US12599647B2 to Xizang Haisco Pharmaceutical Co., Ltd. for a peptide amide composition containing a compound of formula (I) and pH regulators (pH 3-5.5). The composition is designed for treating or preventing diseases or conditions associated with kappa opioid receptors. The patent includes 19 claims and covers the compound composition, preparation methods, and medical applications.

Pharmaceuticals and Dosing Means for Human Aging Reversal

The USPTO granted patent US12599651B2 to Intervene Immune Inc. on April 14, 2026. The patent covers pharmaceutical compositions combining human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin for reversing age-related changes including systemic inflammation, cancer risk, thymus function, immune cell populations, and epigenetic age. The patent contains 11 claims.

SIRPγ Inhibitor for Cancer Treatment | US12599650B2

USPTO granted patent US12599650B2 to AMGEN INC. covering methods of treating tumors or cancer using SIRPγ inhibitors. The patent, invented by Ruozhen Hu, Paolo Manzanillo, and Wenjun Ouyang, contains 9 claims. Filing date was June 23, 2020 (Application No. 17618922).

MaxCyte Electroporation Device Design Patent USD1122471S1

The USPTO granted Design Patent USD1122471S1 to MaxCyte, Inc. for an electroporation device design. The patent application was filed on March 5, 2025, with inventors James William Luther, Bertold Engler, Andrea Besana, and Thomas Alan Peach. One design claim was granted. Design patents protect the ornamental appearance of a functional item for a term of 15 years from grant date.

Biomarker Combinations for NASH and Hepatic Fibrosis Diagnosis

USPTO granted patent US12601747B2 to Bio-Rad Laboratories for biomarker combinations used to diagnose Non-Alcoholic Steatohepatitis (NASH) and hepatic fibrosis status. The patent covers methods and kits for evaluating liver conditions based on three or more biomarker levels in subjects with NAFLD or NASH.

Maize Gene KRN2 and Uses Thereof Patent Grant US12600976B2

The USPTO granted Patent US12600976B2 to China Agricultural University for KRN2 gene technology controlling kernel row number in maize plants and associated molecular markers for molecular breeding applications. The patent contains 6 claims and names six inventors including Xiaohong Yang, Jiansheng Li, Wenkang Chen, Xuan Zhang, Lichun Cai, and Yirong Zhang.

Treating Glioblastoma Using Integrin Pathway Targeting

USPTO granted patent US12601743B2 to The Regents of the University of California for methods of treating drug-resistant glioblastoma (GBM) by targeting the integrin avb3 pathway. The patent covers diagnostic methods to determine tumor sensitivity and treatment methods for tumors identified as avb3+ and Glut3+ with specific molecular signatures. The patent contains 9 claims.

Anti-IgG Nanobodies Patent Granted to Max-Planck

USPTO granted patent US12600799B2 to Max-Planck-Gesellschaft on April 14, 2026 for novel anti-IgG nanobodies directed against rabbit or mouse IgG. The patent contains 11 claims classified under CPC C07K 16/42. The invention also covers methods for producing and using said nanobodies.

Single-Domain Antibodies That Bind ROR1

USPTO granted Patent US12600801B2 to Fred Hutchinson Cancer Center for single-domain antibodies binding receptor tyrosine kinase ROR1. The patent covers anti-cancer therapeutics, antibody-drug conjugates, multi-domain binding molecules, and cancer imaging/diagnostic agents. The patent contains 20 claims with inventors Jason Price, Colin E. Correnti, and James M. Olson.

CD38 Antibody Variant Improves Manufacturing Yield

USPTO granted patent US12600790B2 to Vivasor, Inc. covering a variant anti-CD38 IgG antibody with improved manufacturing yield and a mutated light chain that reduces cleavage heterogeneity. The patent contains 19 claims and is classified under C07K 16/2878 and related CPC codes.

5T4 Binding Polypeptides for Cancer Therapy

USPTO granted patent US12600794B2 to Abdera Therapeutics for 5T4 binding polypeptides useful for cancer therapy. The 36 claims cover polypeptides conjugated to chelating agents or radionuclide complexes. The patent protects compositions and methods for treating 5T4-expressing cancers.

IGF-1R Antibodies With Extended Half-Lives for Thyroid Eye Disease Treatment

USPTO granted US Patent US12600788B2 to Viridian Therapeutics, Inc. covering antibodies and compositions targeting Insulin-Like Growth Factor-1 Receptor (IGF-1R) with extended half-lives for treating thyroid eye disease. The patent contains 18 claims and names six inventors including Vahe Bedian, Peter Harwin, and Jonathan Violin.

Method of Screening Compounds Inhibiting Pancreatic Cancer RNF43 Mutation

The USPTO granted Patent US12600785B2 to Antlera Therapeutics Inc. covering a method of screening compounds that inhibit proliferation of pancreatic cancer cells having a loss-of-function mutation in the RNF43 gene. The patent discloses FZD5-binding agents for treating diseases associated with aberrant Frizzled protein expression. The patent contains 5 claims and names Guohua Pan, Jason Moffat, Sachdev Sidhu, Stephane Angers, Zachary Steinhart, and Xiaowei Wang as inventors.

RAGE Antibodies Patent Granted SUNY Apr 14

USPTO granted Patent US12600778B2 to The Research Foundation for The State University of New York for antibodies specific to the heparan sulfate binding site of Receptor for Advanced Glycation Endproducts (RAGE). The patent includes methods for treating conditions involving RAGE through antibody administration, with 4 claims allowed.

Tumor-Targeted Bispecific CD28 Antigen Binding Molecules Patent Grant

USPTO granted patent US12600781B2 to Hoffmann-La Roche Inc. covering tumor-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28. The patent includes 51 claims covering the binding molecules, methods of production, pharmaceutical compositions containing these antibodies, and methods of using the same for cancer treatment.

Novo Nordisk Patent for IL-6 Antagonist Treatment of Diuretic Resistant Heart Failure

The USPTO granted Patent US12600773B2 to Novo Nordisk A/S on April 14, 2026, covering methods of treating diuretic resistant heart failure patients carrying at least one copy of the TMPRSS6 rs855791 allele by administering an IL-6 antagonist. The patent also covers treatment of patients with elevated urine or plasma IL-6 levels requiring diuresis. The patent (CPC: C07K 16/248) names five inventors and issues from Application No. 17519082 filed November 4, 2021, with 10 claims granted.

LAG-3 Antibody Combination Therapies - Patent US12600777B2

The USPTO granted patent US12600777B2 to Novartis AG covering combination therapies comprising antibody molecules that specifically bind to LAG-3. The patent contains seven claims and relates to methods for treating, preventing, and/or diagnosing cancerous or infectious disorders. This represents a grant of exclusive intellectual property rights to Novartis AG for the therapeutic application of LAG-3 antibody combinations.

IBM Granted Patent for Antigen-Binding Proteins Targeting SARS-CoV-2 Variants

USPTO granted IBM (International Business Machines Corporation) Patent US12600764B2 for antigen-binding proteins capable of binding to SARS-CoV-2 coronavirus variants. The patent covers compositions comprising heavy polypeptide chain variable regions with specific amino acid substitutions (R50, I54, L55 positions) that enhance binding to CoV variants. The patent includes 14 claims and was filed on August 27, 2021.

ASKGENE Pharma Granted Patent for Masked Cytokines

USPTO granted Patent No. US12600762B2 to ASKGENE PHARMA, INC. on April 14, 2026. The patent covers masked cytokines (prodrugs) and methods of use for stimulating the immune system, treating cancer, autoimmune diseases, or infectious diseases. The patent contains 19 claims and was filed on January 11, 2021 under Application No. 17787741.

ENZENE BIOSCIENCES - GLP-1 Receptor Agonist Preparation Process Patent

The USPTO granted patent US12600759B2 to Enzene Biosciences Limited covering processes for preparing glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs. The patent specifically encompasses processes for preparing liraglutide, D-liraglutide, semaglutide, and D-semaglutide in substantially pure form. The application (17440127), filed on March 19, 2020, contains 4 claims and covers both solid and solution phase preparation methods.

Bioniz Therapeutics - Peptide Cytokine Inhibitors Patent Grant US12600757B2

The USPTO granted Patent US12600757B2 to Bioniz Therapeutics, Inc. on April 14, 2026. The patent covers stable peptide antagonists targeting the gamma-c (γc) subunit binding site to inhibit activity of γc-cytokine family members. The 16 claims apply to therapeutic and cosmetic agents as well as research tools for treating diseases associated with γc-family cytokines.

Anti-TDP-43 Binding Molecules and Uses Thereof

The USPTO granted Patent No. US12600766B2 to AC Immune SA covering anti-TDP-43 specific binding molecules, including antibodies and antigen-binding fragments, for diagnosing, preventing, and treating diseases associated with TDP-43 aggregates. The patent lists 15 claims and names Tamara Seredenina, Tamar Magdalena Ziehm, and Tariq Afroz as inventors. The filing date was May 22, 2020, under Application No. 17613444.

Modified S2 Subunit Coronavirus Spike Protein Patent US12600751B2

The USPTO granted patent US12600751B2 to inventors Annika Kraemer-Kuehl and Thomas Min Stephan for a modified S2 subunit of coronavirus spike protein featuring a mutation at amino acid position 865. The patent covers a recombinant avian coronavirus spike protein or fragment thereof, along with an immunogenic composition containing the modified spike protein. The patent includes 22 claims with filing date May 6, 2020.

Cobra 1/NELF-B as Booster for CD8+ T Cell-Based Therapy - US12600755B2

The USPTO granted Patent US12600755B2 to The George Washington University on April 14, 2026. The patent covers methods of generating T cells with integrated transgenes encoding negative elongation factor (NELF) complex subunits, specifically Cobra 1/NELF-B, for use in treating cancer and infectious disease. The patent contains 19 claims.

RSV Vaccine Methods for Inactivating and Stabilizing Pre-F Protein

USPTO granted patent US12600750B2 to Xiamen University covering methods for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein. The patent also covers inactivated RSV virus obtained by the method, vaccines comprising the inactivated virus, and uses of the vaccine for preventing or treating RSV infection. The patent names six inventors including Zizheng Zheng, Wei Zhang, and Ningshao Xia, with 19 claims total.

Native Chemical Ligation Flow Synthesis - University of Sydney

The USPTO granted Patent US12600746B2 to the University of Sydney covering synthetic methods using native chemical ligation in flow for synthesizing polypeptides. The patent, invented by Richard J. Payne and Tim Chisholm, includes 27 claims and covers selective desulfurization or deselenization of amide-containing compounds with thiol, disulfide, selenol, or diselenide functional groups. The patent application was filed on May 22, 2019, under application number 17057069.

Bioactive Polypeptides for Plant Protection, Growth and Productivity

USPTO granted Patent US12599649B2 to Spogen Biotech Inc. covering bioactive priming polypeptides for agricultural applications. The patent protects formulations containing 7 claims that enhance plant growth, yield, health, longevity, productivity, and vigor, while reducing abiotic stress and providing protection from disease, insects, and nematodes. The patent was filed on July 20, 2018.

Affinity Chromatography of Immunoglobulins Using Pre-capture Flocculation

USPTO granted patent US12600748B2 to RICHTER GEDEON NYRT on April 14, 2026. The patent covers methods for purifying immunoglobulins from cell culture harvest using pre-capture cleaning steps including flocculation and filtration before affinity chromatography. The invention improves eluted immunoglobulin quality, reduces precipitation during chromatography, and extends the lifetime of affinity resin used in large-scale immunoglobulin production.

Compstatin Analogues Patent for Complement Inhibitors

USPTO granted patent US12600749B2 to ZP SPV 3 K/S on April 14, 2026, covering compstatin analogues with improved complement-inhibiting activity. The patent includes 19 claims for peptide variants with modifications at positions 3 and 9, as well as terminal sequences, providing improved binding affinity and solubility. Inventors include Anne Pernille Tofteng Shelton, Jacob Ulrik Fog, and Jens Kvist Madsen.

ADAMTS-7 Metalloprotease Peptide Vaccine for Anti-Atherosclerosis - Beijing Kimway

The USPTO granted patent US12599654B2 to Beijing Kimway Biotech Co. Ltd. covering immunogenic peptide fragments of metalloprotease ADAMTS-7 and their use in anti-atherosclerosis vaccines. The patent, granted April 14, 2026 with an original filing date of August 20, 2020, includes 3 claims covering short peptide sequences (SEQ ID NO: 1-4) and vaccine compositions designed to inhibit vascular restenosis and atherosclerosis in mouse models.

Serum Albumin-Binding Fibronectin Type III Domains and Therapeutic Applications

USPTO granted Patent US12599652B2 to Janssen Biotech, Inc. covering fibronectin type III (FN3) domains that specifically bind to serum albumin. The patented technology includes related polynucleotides, cells expressing FN3 domains, and FN3 domains fused to heterologous moieties. The invention is designed to extend half-life of molecules in diagnostic and therapeutic applications.

Multivalent Peptide Conjugates for Intra-Articular Joint Inflammation Treatment

USPTO granted patent US12599663B2 to VALITOR, INC. on April 14, 2026. The patent covers multivalent peptide-polymer conjugates designed for sustained intra-articular treatment of joint inflammation, with 23 claims.

LMP-1 Expressing Cells and Methods of Use Thereof - Dana-Farber Cancer Institute

Dana-Farber Cancer Institute, Inc. has been granted USPTO Patent US12595285B2 covering immunogenic cells expressing LMP1 and methods of use for cancer treatment and T cell activation. The patent, with 15 claims, names Baochun Zhang, Il-Kyu Choi, and Zhe Wang as inventors, with an application filing date of May 13, 2022.

Anti-human P40 protein domain antibody and use thereof

USPTO granted Patent US12595300B2 to Akeso Biopharma, Inc. covering an anti-human P40 protein domain antibody for treating autoimmune diseases. The patent includes 20 claims with specific amino acid sequences for heavy and light chain variable regions (SEQ ID NOs 1, 24 for heavy chain; SEQ ID NOs 6, 11, 13, 15, 17, 25 for light chain).

Fc Variants and IL-8 Antibodies Patent Grant

USPTO granted patent US12595299B2 to Chugai Seiyaku Kabushiki Kaisha covering Fc region variants with improved antigen binding in ion concentration-dependent manner, Fc variants with decreased binding to pre-existing anti-drug antibodies, and novel IL-8 antibodies for pharmaceutical use. The patent contains 17 claims and covers molecules derived from antibody engineering technology.

Anti-NGF Antibody and Antigen-Binding Fragment Patent Grant

USPTO granted Patent US12595298B2 to XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. for an anti-NGF antibody and its antigen-binding fragment, covering the preparation method and therapeutic applications for NGF-mediated diseases. The patent includes 6 claims and was filed on August 2, 2021.

Methods to Decrease Impurities from Recombinant Protein Manufacturing Processes

The USPTO granted Patent US12595294B2 to Hoffmann-La Roche Inc. on April 7, 2026. The patent covers methods for reducing non-aggregate produce-related impurities (NAPRIs) in buffered solutions of monoclonal antibodies using synthetic depth filters. Inventors are Marc Pompiati and Christoph Feistl, with 15 claims in the granted patent.

Vasopressin-2 receptor antagonist peptides and uses thereof

The USPTO has granted Patent US12595288B2 to Commissariat à l'Énergie Atomique et aux Énergies Alternatives covering vasopressin-2 receptor antagonist peptides. The patent protects peptide sequences with at least 80% amino acid identity to SEQ ID NO. 1, with specific modifications at variable positions enabling therapeutic applications. The grant includes 14 claims.